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Result Content View
[2003] [THU0293] LYMPHOCYTE APOPTOSIS, MACROPHAGE FUNCTION AND DISEASE ACTIVITY 
IN SYSTEMIC LUPUS ERYTHEMATOSUS 
 
O. Jin 1, L. Sun 1, K. Zhou 1, X. Zhan 1, M. Mok 2, C. Lau 2 1Rheumatology, Drum Tower Hospital, 
Nanjing, 2Rheumatology, Department of Medicine,Hong Kong University, HongKong, China 
 
Background: The origin of numerous autoantibodies in SLE remains an enigma. Increased lymphocyte 
apoptosis and defects in macrophage removal of apoptotic cells have been suggested to contribute to the 
development of SLE. The reason why macrophages have defects in the clearance of apoptotic cells is 
unclear. 
Objectives: To investigate the relationship between peripheral lymphocyte apoptosis, macrophage function 
as determined by the serum levels of neopterin and gama-interferon (gama-IFN), and SLE disease activity. 
Methods: Peripheral apoptotic lymphtocytes (AL) were detected by annexin V-FITC staining and flow 
cytometry. Serum levels of neopterin and gama-IFN were measured by ELISA. SLE disease activity was 
determined using the systemic lupus activity measure (SLAM). 
Results: (1) The % of AL in the peripheral blood of active SLE patients was significantly higher (13.07
±7.39%, n=30) than that of the inactive SLE patients (4.08±3.55%, n=8, p<0.001) and normal controls (5.13
±3.37%, n=11, p<0.001). (2) Serum levels of neopterin in SLE patients were significantly higher (1.39±1.10 
mg/dl, n=22) than in controls (0.26±0.19 mg/dl, n=20, p<0.01). (3) Serum levels of gama-IFN in active SLE 
patients were elevated (58.97±34.52 ng/l, n=15) when compared with controls (28.06±2.35 ng/l, n=16, 
p<0.05). (4) The % of AL correlated significantly with serum levels of neopterin (r=0.446, p<0.05, n=22) and 
SLAM score (r=0.533, p<0.001, n=38), but not with the serum levels of gama-IFN. The SLAM score was 
also correlated with the serum levels of neopterin (r=0.485, p<0.05, n=22) but not with those of gama-IFN. 
Conclusion: 1. Our study supported the hypothesis that increased lymphocyte apoptosis has a pathogenic 
role in SLE. 2. The increased levels of serum neopterin which are mainly released by actived macrophages 
may suggest an attempt of the patients' macrophage system to remove the apoptotic cell excess. 3. Since 
serum levels of neopterin are correlated with the % of apoptotic lymphocytes, so no imbalance was found 
between the macrophage cytokine production and increased lymphocyte apoptosis, suggesting that defects 
in removal of apoptotic cells by macrophages may be influenced by other factors, rather than a primary 
macrophage functional incapability. 4. Since serum levels of neopterin correlated with the lupus disease 
activity, they may be regarded as an index of SLE disease activity.1. Emlen W, Niebur J, Kadera R. 
Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. Journal of 
Immunology, 1994, 152(7):3685-3693.; 2. Baumann I, Kolowos W, Voll RE, et al. Impaired uptake of 
apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus 
erythematosus. Arthritis and Rheumatism, 2002, 46(1):191-201.; 3. Hamerlinck FF. Neopterin: a review. 
Exp Dermatol,1999, 8(3):167-76. 
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